Premium
Alosetron does not affect the visceral perception of gastric distension in healthy subjects
Author(s) -
ZERBIB F.,
VARANNES S. BRULEY des,
ORIOLA R. C.,
McDONALD J.,
ISAL J. P.,
GALMICHE J. P.
Publication year - 1994
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1994.tb00307.x
Subject(s) - medicine , distension , barostat , gastric distension , placebo , crossover study , stomach , anesthesia , pathology , alternative medicine
SUMMARY Background: The effect of alosetron, a new specific 5‐HT 3 , receptor antagonist, on the visceral perception in response to gastric distension was assessed in 12 healthy male subjects in a randomized, double‐blind, placebo controlled crossover trial Methods: Each subject was given orally either alosetron 1 mg b.d. or placebo b.d. for 6 days (wash‐out period 7–28 days). At the end of each dosing period, both isobarometric and isovolumetric gastric distensions were performed using an electronic barostat. Results: Alosetron did not modify the gastric wall compliance (pressure‐volume relationship). Alosetron had an effect similar to placebo on the visceral perception scores in both isobarometric and isovolumetric distensions. The mean (± SEM) thresholds for abdominal discomfort were, respectively, 16.8 ±0.7 mmHg and 825 ± 61 mL with alosetron, 16.7±0.6 mmHg and 883±45 mL with Placebo (P = NS). Conclusions: 5‐HT 3 receptors do not appear to be involved in the visceral perception of gastric distension in healthy subjects.